Copyright © 2025 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{149338,
        author = {Devanand N. Kumbhar and Nandkishor B. Bavage and Shyamlila B. Bavage and Vidyasagar Gali},
        title = {A review on Ebola virus disease},
        journal = {International Journal of Innovative Research in Technology},
        year = {},
        volume = {6},
        number = {12},
        pages = {1-5},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=149338},
        abstract = {Ebola virus is transmitted to people as a result of direct contact with body fluids containing virus of an infected patient. The incubation period usually lasts 5 to 7 d and approximately 95% of the patients appear signs within 21 d after exposure. Typical features include fever, profound weakness, diarrhoea, abdominal pain, cramping, nausea and vomiting for 3-5 days and maybe persisting for up to a week. Laboratory complications including elevated aminotransferase levels, marked lymphocytopenia, and thrombocytopenia may have occurred. Hemorrhagic fever occurs in less than half of patients and it takes place most commonly in the gastrointestinal tract. The symptoms progress over the time and patients suffer from dehydration, stupor, confusion, hypotension, multi-organ failure, leading to fulminant shock and eventually death. The most general assays used for antibody detection are direct IgG and IgM ELISAs and IgM capture ELISA. An IgM or rising IgG titter (four-fold) contributes to strong presumptive diagnosis. Currently neither a licensed vaccine nor an approved treatment is available for human use. Passive transfer of serum collected from survivors of Junín virus or Lassa virus, equine IgG product from horses hyper vaccinated with Ebola virus, a “cocktail” of humanized-mouse antibodies (ZMapp), recombinant inhibitor of factor VII  a/tissue factor, activated protein C, RNA-polymerase inhibitors and small interfering RNA nano particles are among the therapies in development.},
        keywords = {Ebolavirus, Epidemiology, Pathophysiology, Treatment, Pandemic Research},
        month = {},
        }